Scientists train Patients' own cells to fight metastatic cancer
NCT ID NCT01174121
Summary
This study tests whether a patient's own immune cells, removed from their tumor and multiplied in a lab, can shrink tumors when given back alongside the drug pembrolizumab. It's for adults with advanced digestive tract, breast, ovarian, or other cancers that have spread and stopped responding to standard chemotherapy. The goal is to see if this personalized cell therapy is safe and can control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.